Recruiting

Microarrays in Heart Transplantation

Sponsor:

University of Alberta

Code:

NCT02670408

Conditions

Cardiac Transplant Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Endomyocardial biopsy

Study Details

Brief summary:

Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.

Conditions

Cardiac Transplant Disorder

Study ID

NCT02670408

Start date

Jan, 2016

Status verified date

Jun, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • biopsy for clinical indications

Exclusion Criteria:

  • no consent
  • pregnant women

Study Design

Enrollment

900 participants

Anticipated

Interventions and Outcome Measures

Interventions

Endomyocardial biopsy

One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.

Primary outcome measure

  • Assign molecular scores (probability) of T cell mediated rejection, antibody mediated rejection in heart transplant biopsies, in a reference set of 200 biopsies [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Konrad S Famulski, PhD

1 7804921725konrad@ualberta.ca

Robert Polakowski, PhD

1780 492 5091polakows@ualberta.ca

Locations

Alberta Transplant Applied Genomics Center, University of Alberta

Recruiting

Edmonton, Alberta, Canada, T6G 2E1

Contacts

Konrad Famulski, PhD

7804921725konrad@ualberta.ca

Principal Investigator:

Philip F Halloran, MD PhD

More Information

Sponsor

University of Alberta

Last update posted

Jun 4, 2026

Last verified

Jun, 2026

Keywords

  • Heart transplant
  • global gene expression
  • molecular diagnostics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Alberta on 2026-06-04.